Pharmanutra stock
PHN.MIMILPharmanutra S.p.A., HealthcareISIN IT0005274094
62Score 62 out of 100, Neutral
Price and trend
59 / 100
Price history
+67% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 7.1% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 87).
The price is 9.5% below its 52-week high. Largest decline in 9 years: 50% (January 2022 to October 2025).
Chart figures for advanced users
- SMA 50$81.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$86.98
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)87
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$55.41
- The lowest closing price of the last twelve months.
- Resistance$102.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pharmanutra S.p.A. belongs to the Drug Manufacturers (Specialty & Generic) industry (Italy) and, with a market value of $892.32M, is number 66 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $145.92M (up 13.4% year on year) and earnings of $22.16M (up 20.4%).
- For fiscal 2026, analysts expect on average revenue of $172.6M (up 18.3%) and adjusted earnings per share of $2.79 (up 21.4%).
Show more
- MEQIRI Score 62 out of 100 (Neutral): rank 242 of 702 in Healthcare, median 53.
- The P/E is 34.7 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 26.9).
- Our model puts fair value at $69.52, with the price 34% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 33.7% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 58
- Growing faster than its industryRevenue up 17.6% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 77
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 63
Weaknesses
- Richly valuedP/E 34.7, Drug Manufacturers (Specialty & Generic) median 18.9, own median 26.9.Valuation 36
Its standout strengths are stability and momentum, while valuation and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $53.48 and expensive above $99.32 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $88.29 (cash-flow model) and $50.76 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.9%. At 9.9% the fair value would be $61.88, at 7.9% it would be $80.74.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.9% on the twelve months before. Revenue has grown strongly since 2015, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 23%, operating 23%, net 15%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 12 Mar 2027in 119 days
- Last reported
- 9 Nov 2026EPS reported $0.94 (expected $0.94)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.790.0%
- Revenue
- $172.6M0.0%
- Earnings per share
- $3.520.0%
- Revenue
- $202.37M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Pharmanutra
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- BioGaiaBIOG-B.ST $1.24B77
- Amphastar PharmaceuticalsAMPH $1.23B75
- VetoquinolVETO.PA $1.14B77
- Harrow HealthHROW $1.06B38
- Ironwood PharmaceuticalsIRWD $802.92M72
- Collegium PharmaceuticalCOLL $775.33M51
- EvotecEVT.DE $613.98M32
- Alpha TeknovaTKNO $522.1M44
ETFs that hold Pharmanutra
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.04% | 0.58% | €838.19M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.03% | 0.40% | €580.62M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.02% | 0.23% | €321.86M |
Show 4 more
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.02% | 0.30% | €3.45B |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.01% | 0.34% | €16.96M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.00% | 0.30% | €813.64M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.